id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-000174-mgj9zfft	Slavenburg, Serena	Pneumonitis as A Consequence of (Peg)Interferon-Ribavirin Combination Therapy for Hepatitis C: a Review of the Literature	2009-04-28		.txt	text/plain	3198	178	40	Pulmonary toxicity in patients undergoing HCV combination treatment is rare, and may include interstitial pneumonitis, sarcoidosis, pleuritis, bronchiolitis obliterans organizing pneumonia (BOOP), and exacerbation of asthma [6, 7] . Interstitial pneumonitis occurs only rarely as a side-effect of HCV combination treatment and often leads to discontinuation of therapy, which has great implications for patients. In this article we presented our case of pneumonitis during combination therapy and performed a review in order to generate guidelines to manage symptoms and treatment. In most cases, symptoms of pneumonitis are reversible after cessation of treatment with (peg)interferon and ribavirin, again in support of drug-induced interstitial pneumonitis. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C. Interstitial pneumonitis during combination therapy with interferon-a and ribavirin in a patient with chronic hepatitis C Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C	./cache/cord-000174-mgj9zfft.txt	./txt/cord-000174-mgj9zfft.txt